Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Vaxil (VXL), a biotech company, has signed a non-binding letter of intent to acquire a 100 per cent stake in ShortWave Pharma
  • Consideration for the transaction will be $2.5 million payable in units
  • Each unit will consist of one common share in the capital of Vaxil and one purchase warrant exercisable for an additional common share, upon paying a base exercise price $0.20, any time for three years after closing the transaction
  • When the transaction is completed Vaxil will allow Shortwave to nominate one person to its board of directors
  • Vaxil Bio Ltd. Is up 10 per cent and is trading at $0.11 at 1:03 p.m. ET

Vaxil (VXL), a biotech company, has signed a non-binding letter of intent to acquire a 100 per cent stake in ShortWave Pharma.

ShortWave Pharma’s initial pre-clinical program is focused on treatment-resistant eating disorders, an underserved area with high mortality and morbidity. Early clinical data suggests psychedelics may play a beneficial role in therapy.

Vaxil will pay $2.5 million in units for the acquisition.

Each unit will consist of one common share in the capital of Vaxil and one purchase warrant exercisable for an additional common share, upon paying a base exercise price $0.20, any time for three years after closing the transaction.

The units will be subject to an agreed-upon contract lock-up based on the following schedule:

  1. 50 per cent will be released from any trading restrictions on the 6-month anniversary of the closing
  2. 25 per cent will be released from any trading restrictions on the 9-month anniversary of the closing
  3. 25 per cent will be released from any trading restrictions on the 12-month anniversary of the closing

When the transaction is completed Vaxil will allow Shortwave to nominate one person to its board of directors.

The acquisition is subject to the approval of the TSXV and the completion of a private placement financing.

Vaxil Bio Ltd. Is up 10 per cent and is trading at $0.11 at 1:03 p.m. ET.

More From The Market Herald
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais

" Theratechnologies (TSX:TH) confirms effectiveness of PDCs against vasculogenic mimicry

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" MediPharm Labs (TSX:LABS) appoints new CEO

 MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15,

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.